# US 2024/0390403 A1 · Composition and methods for treating an aneurysm

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390403 A1
- Document ID: US20240390403A1
- Status: Published application
- Kind: A1
- Application number: 18/674,433
- Filed: 2024-05-24
- Published: 2024-11-28
- Earliest claimed: 2023-05-25
- Assignees: Nectero Medical, Inc.
- Applicants: Nectero Medical, Inc.
- Inventors: Alexander Schwarz
- Web page: https://patentgrep.com/patent/US20240390403A1

## CPC

- A61K 31/7024: Esters of saccharides
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/09: having two or more such linkages
- A61K 31/7016: Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032)
- A61K 49/0438: {Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are pollygalloyl compounds of Formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), or (XI), including pharmaceutically acceptable salts thereof, and methods and uses thereof. Compounds disclosed herein may be provided in a kit, including a solubilizer for dissolving the compound or composition as described herein and a saline solution. Also disclosed herein are methods for delivery of a therapeutic solution to a blood vessel.

## Claims

### Claim 1

A method of reducing or inhibiting growth of an aneurysm in a subject having an aneurysm, the method comprising:
administering a composition comprising at least one polygalloyl compound, or a salt thereof, a water-soluble solubilizer, and a buffer,
wherein the polygalloyl compound is not pentagalloyl β-glucose (β-PGG).

### Claim 2 (depends on 1)

The method of claim 1, wherein the aneurysm is selected from an aortic aneurysm, a peripheral aneurysm, abdominal aortic aneurysm, or a neuro aneurysm.

### Claim 3 (depends on 2)

The method of claim 2, wherein the aortic aneurysm is greater than 3 cm in diameter.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition is administered by local delivery by a catheter device.

### Claim 5 (depends on 1)

The method of claim 1, wherein the at least one polygalloyl compound is fully gallic acid substituted monosaccharides or disaccharides with the proviso that the one or more polygalloyl compound is not β-PGG.

### Claim 6 (depends on 1)

The method of claim 1, wherein the polygalloyl compound is selected from the group consisting of polygalloyl galactose, polygalloyl xylose, polygalloyl ribose, polygalloyl arabinose, polygalloyl fructose, polygalloyl inositol, polygalloyl allose, polygalloyl talose, polygalloyl idose, polygalloyl gulose, polygalloyl erthrose, polygalloyl threose, polygalloyl sucrose, polygalloyl lactose, polygalloyl maltose, polygalloyl maltose, polygalloyl isomaltose, polygalloyl kojibiose, polygalloyl nigerose, polygalloyl laminaribiose, polygalloyl mannobiose, polygalloyl chitobiose, polygalloyl fucosyllactose, polygalloyl galactobiose, polygalloyl rutinose, polygalloyl neotrehalose, polygalloyl leucrose, polygalloyl trehalose, polygalloyl cellobiose, polygalloyl sorbitol, polygalloyl mannitol, polygalloyl maltitol, polygalloyl galactitol, polygalloyl fucitol, polygalloyl isomalt, polygalloyl xylitol, polygalloyl ribitol, polygalloyl ribitol, polygalloyl arabitol, polygalloyl erythritol, or combinations thereof.

### Claim 7 (depends on 6)

The method of claim 6, wherein the at least one polygalloyl compound is a compound of Formula (III):

### Claim 8 (depends on 6)

The method of claim 6, wherein the at least one polygalloyl compound is a compound of Formula (IV):

### Claim 9 (depends on 6)

The method of claim 6, wherein the at least one polygalloyl compound is a compound of Formula (V):

### Claim 10 (depends on 1)

The method of claim 1, wherein the at least one polygalloyl compound is a compound of Formula (VI):

### Claim 11 (depends on 1)

The method of claim 1, wherein the at least one polygalloyl compound is a compound of Formula (VII):

### Claim 12 (depends on 1)

The method claim 1, wherein the at least one polygalloyl compound is a compound of Formula (VIII):

### Claim 13 (depends on 6)

The method of claim 6, wherein the at least one polygalloyl compound is a compound of Formula (IX):
wherein, G is galloyl.

### Claim 14 (depends on 6)

The method of claim 6, wherein the wherein the at least one polygalloyl compound is a compound of Formula (X):
wherein, G is galloyl.

### Claim 15 (depends on 6)

The method claim 6, wherein the at least one polygalloyl compound is a compound of Formula (XI):
wherein, G is galloyl.

### Claim 16 (depends on 6)

The method of claim 6, wherein the water-soluble solubilizer is a contrast agent.

### Claim 17 (depends on 16)

The method of claim 16, wherein the contrast agent is a radiocontrast material from about 10 to about 30% (w/v) of the composition.

### Claim 18 (depends on 17)

The method of claim 17, wherein the contrast agent is a radiocontrast material is a non-ionic radio-opaque contrast agent selected from the group consisting of iopamidol, iohexol, iodixanol, or a combination thereof.

### Claim 19

A method for treating, preventing, ameliorating, or reducing an aortopathic condition or disease in a subject in need thereof, the method comprising:
administering a composition comprising a polygalloyl compound, or a salt thereof, a water-soluble solubilizer, and a buffer,
wherein the polygalloyl compound is not pentagalloyl β-glucose (β-PGG).

### Claim 20

A method for blood vessel elastin stabilization in a subject in need thereof, the method comprising,
administering a composition comprising a polygalloyl compound, or a salt thereof, a water-soluble solubilizer, and a buffer,
wherein the polygalloyl compound is not pentagalloyl β-glucose (β-PGG).
